These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 30953540)

  • 21. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
    Curtis JR; Lee EB; Martin G; Mariette X; Terry KK; Chen Y; Geier J; Andrews J; Kaur M; Fan H; Nduaka CI
    Clin Exp Rheumatol; 2017; 35(4):614-622. PubMed ID: 28240592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
    Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
    [No Abstract]   [Full Text] [Related]  

  • 23. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
    Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
    Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    Ytterberg SR; Bhatt DL; Mikuls TR; Koch GG; Fleischmann R; Rivas JL; Germino R; Menon S; Sun Y; Wang C; Shapiro AB; Kanik KS; Connell CA;
    N Engl J Med; 2022 Jan; 386(4):316-326. PubMed ID: 35081280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
    Panés J; D'Haens GR; Sands BE; Ng SC; Lawendy N; Kulisek N; Guo X; Wu J; Vranic I; Panaccione R; Vermeire S
    United European Gastroenterol J; 2024 Jul; 12(6):793-801. PubMed ID: 38778549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
    Lomonte ABV; Radominski SC; Marcolino FMD; Brenol CV; Zerbini CAF; García EG; Akylbekova EL; Rojo R; de Leon DP
    Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tofacitinib: A Review in Psoriatic Arthritis.
    Paik J; Deeks ED
    Drugs; 2019 Apr; 79(6):655-663. PubMed ID: 30895473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
    Cohen S; Radominski SC; Gomez-Reino JJ; Wang L; Krishnaswami S; Wood SP; Soma K; Nduaka CI; Kwok K; Valdez H; Benda B; Riese R
    Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
    J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
    Fleischmann R; Kremer J; Tanaka Y; Gruben D; Kanik K; Koncz T; Krishnaswami S; Wallenstein G; Wilkinson B; Zwillich SH; Keystone E
    Int J Rheum Dis; 2016 Dec; 19(12):1216-1225. PubMed ID: 27451980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
    Sandborn WJ; Panés J; D'Haens GR; Sands BE; Su C; Moscariello M; Jones T; Pedersen R; Friedman GS; Lawendy N; Chan G
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
    Gladman DD; Charles-Schoeman C; McInnes IB; Veale DJ; Thiers B; Nurmohamed M; Graham D; Wang C; Jones T; Wolk R; DeMasi R
    Arthritis Care Res (Hoboken); 2019 Oct; 71(10):1387-1395. PubMed ID: 31112005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tofacitinib versus methotrexate in rheumatoid arthritis.
    Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
    N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
    Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E
    Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
    Bird P; Bensen W; El-Zorkany B; Kaine J; Manapat-Reyes BH; Pascual-Ramos V; Witcombe D; Soma K; Zhang R; Thirunavukkarasu K
    J Clin Rheumatol; 2019 Apr; 25(3):115-126. PubMed ID: 29794874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
    Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
    Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
    Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.